With results from six randomized controlled trials, three systematic reviews, and more than 40,000 patients, the study is the first synthesis of its kind
Prescription GLP-1 receptor agonist medications have received significant attention following clinical trial outcomes
A patient might use the upper leg, upper arm, or stomach as the injection site and change them from time to time
While serious complications from a single dose of degraded medication are uncommon, prompt medical evaluation ensures appropriate management if problems arise
Ozempic as an add-on to basal insulin and Ozempic 1 mg vs 2 mg Primary endpoint: change in A1C from baseline SUSTAIN 5: add-on basal insulin 1,10,11 In adult patients with type 2 diabetes on basal insulin metformin Mean change in A1C from baseline at Week 30 Mean baseline A1C: SUSTAIN FORTE: Ozempic 1 mg vs 2 mg 1,8 In patients with type 2 diabetes on metformin sulfonylurea Mean change in A1C from baseline at Week 40 Mean baseline A1C: Results for SUSTAIN 5 and SUSTAIN FORTE based on sensitivity analyses of retrieved dropout population